GlassScriptPhysician profile
Daniel J Curry
NPI 1346305174
$51,509.73
in general payments reported to CMS, 2019-2025
10 companies · $3,113 in 2025
The $3,113 reported for 2025 was more than what 75% of Neurological Surgery providers received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,080 · 2020: $9,060 · 2021: $17K · 2022: $2,153 · 2023: $8,221 · 2024: $3,900 · 2025: $3,113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $10K · Travel and Lodging: $3,150 · Food and Beverage: $1,772.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $10,312.50 |
| Travel and Lodging | $3,149.94 |
| Food and Beverage | $1,771.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $14,528.43 | 2019-2020 | |
| Aesculap, INC. | $13,656.87 | 2021 | |
| Ptc Therapeutics, INC. | $11,612.50 | 2020-2023 | |
| Neuropace, INC. | $3,968.66 | 2019-2024 | |
| Clearpoint Neuro, INC. | $3,101.32 | 2023-2025 | Clearpoint |
| Medtronic, INC. | $2,938.68 | 2021-2025 | Visualase |
| Insightec,INC | $1,578.39 | 2019-2022 | |
| Monteris Medical Corporation | $45.55 | 2021 | |
| Abbott Laboratories | $41.44 | 2025 | Infinity |
| Olympus America INC. | $37.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Curry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.